INSM Insmed Inc

Insmed Incorporated (NASDAQ: INSM) announces updated results for the Company's pivotal Phase III clinical trial evaluating SomatoKine(R) (mecasermin rinfabate), a once daily insulin-like growth factor I (IGF-I) replacement therapy delivered as a proprietary complex of rhIGF-I/rhIGFBP-3, in children with short stature due to growth hormone (GH) insensitivity syndrome (GHIS). The primary endpoint of change in height velocity after 6 months on treatment was achieved and was highly statistically significant (p